BioChaperone PDGF-BB: Interim Phase II data

Interim data from an open-label, Indian Phase II trial in patients with diabetic foot ulcers showed that BioChaperone PDGF-BB applied once every 2 days was non-inferior to daily Regranex becaplermin ...